WO2005100354A1 - ピラゾール縮合環誘導体の製造方法 - Google Patents
ピラゾール縮合環誘導体の製造方法 Download PDFInfo
- Publication number
- WO2005100354A1 WO2005100354A1 PCT/JP2005/006928 JP2005006928W WO2005100354A1 WO 2005100354 A1 WO2005100354 A1 WO 2005100354A1 JP 2005006928 W JP2005006928 W JP 2005006928W WO 2005100354 A1 WO2005100354 A1 WO 2005100354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- atom
- compound
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a pyrazole fused-ring derivative (7F2) which is useful as a corticotropin-releasing factor (CRF) receptor antagonist for the prevention or treatment of depression, anxiety and the like.
- Method for producing pyrazole-condensed ring derivatives such as birazolo [1,5-a] pyridine derivatives
- pyrazole-condensed ring derivatives such as birazolo [1,5-a] pyridine derivatives
- RCF corticotropin-releasing factor
- the compound represented by or a salt thereof or a solvate thereof is novel and has not been known until now.
- Pentafluoroiodobenzene is a known compound, and there is no example used as a reagent in a force iodination reaction. Further, in the iodination reaction of pyrazole fused ring derivatives (such as birazolo [1,5-a] pyridine derivatives), there are reports using n-butyllithium and 1,2-jodoethane as described above (Patent Document 1 and Patent Document 2).
- Patent Document 1 International Publication No. 02Z088121 pamphlet
- Patent Document 2 International Publication No. 03Z078435 pamphlet
- Patent Document 3 International Publication No. OOZ59908 pamphlet
- Patent Document 4 International Publication No.OOZ59907 pamphlet
- Non-Patent Document 1 J. Am. Chem. Soc, 7421-7428, 124, 2002
- An object of the present invention is to provide (1) a pyrazole condensed ring derivative (Virazo-mouth [ The present invention relates to a method for producing a 1,5-a] pyridine derivative or the like and (2) a pyrazole condensed ring derivative (7-pyridazo [1,5-a] pyridine derivative or the like) or a salt thereof or a solvate thereof.
- pyrazole condensed ring derivatives such as the above 7-phenylavizolo [1,5-a] pyridine derivatives
- Z 1 and Z 2 each independently represent a methine group or a nitrogen atom.
- R 5 represents a hydrogen atom or a C alkyl group.
- R 1 is a group represented by the formula —R 1C> —R 11 (wherein, R 1C> represents a single bond, an oxygen atom or a sulfur atom; R ] 1 represents a methyl group or an ethyl group) or It means a methoxymethyl group.
- R 2 and R 3 are each independently a hydrogen atom, a t-butoxycarbol group or a formula —X 21 —X 31 (where X 21 represents a methylene group or a carbyl group; x 31 is C Archi
- a radical Means a group represented by).
- organometallic compounds It is characterized by reacting with pentafluoroiodobenzene after reacting with reagent
- organometallic reagent is n-butyllithium, t-butyllithium, sec-butyllithium, phenyllithium, lithium diisopropylamide, n-butylmagnesium bromide or isopropylmagnesium bromide.
- Iodine is used in an amount of 1 to 2 moles (more preferably 1.4 to 1.6 times the mole) with respect to the amount of pentafluoroiodobenzene [1], [2], [3] ], [3.1], [3.2], [3.3] or [3.4]
- a metal catalyst such as a copper catalyst or a palladium catalyst
- a phosphate and an amine compound the formula
- R 4 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom or a formula
- R 41 , R 4 and R 4d each independently represent (1) a hydrogen atom, (2) a halogen atom, (3) a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a C alkoxy group, a pyrrolidine -Le group,
- a group having one or two selected groups which may mean a C alkyl group
- R u and R dU are each independently a hydrogen atom or a formula — X — X (wherein X ′ 2 represents a methylene group or a carbonyl group; X 32 is C alkyl) Group, C cycloa
- 1-6 3-8 means alkyl, tetrahydropyranyl or tetrahydrofuranyl. ) Means a group represented by. Wherein the compound is reacted with a compound represented by the formula:
- R 2 °, R 3 ° and R 4 are the R 2 °, the same meaning respectively R 3 ° and R 4.
- Z Z 2, R 1 and R 5 are the above [1] Stated It is the same as R 1 and R 5 respectively.
- the metal catalyst is copper iodide 0), copper iodide ( ⁇ ), copper bromide (1), copper bromide (11), copper chloride (1), copper chloride (11), copper acetate 0), copper acetate ( II) or the production method according to the above [4], which is copper oxide.
- the phosphate is tri-potassium phosphate, di-potassium hydrogen phosphate, tri-sodium phosphate, disodium hydrogen phosphate, trilithium phosphate, dilithium hydrogen phosphate or magnesium phosphate or Is the hydrate thereof, the production method according to the above [4] or [5].
- reaction of the compound represented by the formula (6) with the compound represented by the formula (IV) is performed at 50 to 200 ° C (more preferably 90 to 150 ° C), the above (4), (5), (6) ] Or [7].
- the copper catalyst is used in an amount of 0.001 to 1.0 mole (more preferably 0.18 to 0.22 mole) based on the amount of the compound represented by the formula (III). 4], [5], [6], [7] or [7.1] V.
- the compound represented by the formula (IV) is used in an amount of 1.0 to 3.0 times by mole (more preferably 1.0 to 1.5 times by mole) the amount of the compound represented by the formula ( ⁇ ).
- the phosphate is used in an amount of 1.0 to 5.0 moles (more preferably 1.8 to 2.2 moles) based on the amount of the compound represented by the formula (III). 4], [5], [6], [7], [7.1], [7.2] or [7.3].
- the amount of the compound represented by the formula ( ⁇ ) is 0.001 to 1.0 times the molar amount of the amide compound (more preferably 0.38 to 0.42 times the molar amount). ], [5], [6], [7], [7.1], [7.2], [7.3] or [7.4].
- a pyrazolyl condensed ring derivative such as a 7-pyodopyrazo [1,5-a] pyridine derivative
- a salt thereof which is a crystalline substance that can be isolated and purified without using column chromatography.
- a pyrazole fused ring derivative having CRF receptor antagonistic activity (the above-mentioned 7-Fe (1) Method for producing pyrazolyl fused ring derivatives (such as birazolo [1,5-a] pyridine derivatives) useful as intermediates for the synthesis of -lupyrazolo [1,5-a] pyridine derivatives and (2) It was possible to provide a pyrazole fused ring derivative (such as a 7-odopyrazo [1, 5, 5-a] pyridine derivative), a salt thereof, or a solvate thereof.
- the structural formula of a compound may represent a certain isomer for convenience.
- the present invention relates to all geometric isomers, optical isomers based on asymmetric carbons, It includes all isomers such as isomers and tautomers, and isomer mixtures, and is not limited to the description of formulas for convenience.
- n- indicates normal, "sec-” indicates secondary, and "tert-” or “t-one” indicates tertiary.
- Z 1 and Z 2 means a methine group or a nitrogen atom each independently, preferably a force Z 1 and Z 2 means a methine group or Z 1 and Z 2,, displacement or the other force methine group And the other means a nitrogen atom, more preferably Z 1 and Z 2 mean a methine group, or Z 1 means a nitrogen atom and Z 2 means a methine group More preferably, Z 1 and Z 2 represent a methine group.
- R 5 is a force means a hydrogen atom or a C alkyl group and preferably a hydrogen atom.
- R 1 represents a group represented by the formula: —R 1C> —R 11 (wherein, R 1C> represents a single bond, an oxygen atom or a sulfur atom; R 11 represents a methyl group or an ethyl group) or A methoxymethyl group is preferred, with preferred examples being a methyl group, an ethyl group, a methoxy group, a methylthio group, an ethoxy group or a methoxymethyl group, and more preferred is an ethyl group, a methoxy group or a methoxymethyl group. It is a luthio group, more preferably an ethyl group.
- R 2 and R 3 are each independently a hydrogen atom, t-butoxycarbonyl group, or a group of the formula _ ⁇ 21 _ ⁇ 31 (wherein, X 21 represents a methylene group or carbo - means Le group; chi 31 is c Al
- R 2 and R 3 are each independently an ⁇ -propyl group, an ⁇ -butyl group, a (cyclobutyl) methyl group, a cyclopropylmethyl group, a (tetrahydrovinyl) methyl group, a (tetrahydrofural) ) A methyl group. More preferably, R 2 and R 3 are each independently a cyclopropylmethyl group, a (4-tetrahydrofural) methyl group, a (3-tetrahydrofural) methyl group or a (2-tetrahydrofural) methyl group Group.
- R 2 is cyclopropylmethyl or (4-tetrahydrovinyl) methyl, most preferably R 2 is cyclopropylmethyl, and is (4-tetrahydrovinyl) methyl. Means the group.
- X represents a leaving group.
- X is preferably a bromine atom, an iodine atom or a C alkylsulfonyloxy group optionally substituted with 1 to 5 halogen atoms, although it is not particularly limited as long as it is a leaving group used in an organic chemical reaction. More preferably bromine
- Atom iodine atom or trifluoromethylsulfonyloxy group, more preferably iodine atom.
- R 2G and R 3G are each independently a hydrogen atom or a formula — X 22 — X 32 (where X 22 represents a methylene group or a carbyl group; X 32 represents a C alkyl group, a C cycloalkyl group).
- a tetrahydropyranyl group or a tetrahydrofuranyl group. Means a group represented by.
- R 2 ° is a hydrogen atom
- R 3 ° is a group represented by the formula — X 42 -X 32 (wherein X 42 represents a carboxyl group; X 32 is a C alkyl group, a C cycloalkyl group , Tetrahydropyran—
- R 2U is a hydrogen atom
- R d is a tetrano or hydropropyl-carbonyl group.
- R 4 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom or a formula
- R 41 , R 4 ⁇ and R 4d each independently represent (1) a hydrogen atom, (2) a halogen atom, (3) a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a C alkoxy Group, pyrrolidyl group,
- It may have one or two groups selected from the group consisting of a pyranyl group and a tetrahydrofuranyl group, and may have a C alkoxy group or (4) a fluorine atom, a chlorine atom, a bromine atom,
- a group having one or two selected groups which may mean a C alkyl group
- R 41 , R 42 , and R 43 include R 4 °, two of R 41 and R 42 represent a methoxy group, and more preferably R 4 and R 42 represent a methoxy group.
- R 4 is a hydrogen atom.
- the "pyrrolidinyl group” is a monovalent group derived by removing one arbitrary hydrogen atom from the pyrrolidine force, and specifically, for example, a 1-pyrrolidyl group, a 2-pyrrolidyl group or a 3-pyrrolidyl group. It means a lysinyl group.
- the “piperazyl group” is a monovalent group derived by removing one arbitrary hydrogen atom from piperazine, and specifically, for example, a 1-piperazinyl group, a 2-piperazyl group, a 3-piperidyl group Radinyl group or 4-piperazinyl group.
- Porture group refers to a piperidine force, a monovalent derivative derived by removing one hydrogen atom. And specifically means, for example, a 1-piperidyl group, a 2-piperidyl group, a 3-piperidyl group or a 4-piperidyl group.
- morpholinyl group is a monovalent group derived by removing one arbitrary hydrogen atom from morpholine, and specifically means, for example, a 2 morpholinyl group, a 3 morpholinyl group or a 4 morpholinyl group.
- tetrahydropyran-1-yl group is a monovalent group derived from tetrahydropyran by removing one arbitrary hydrogen atom, and specifically, for example, a tetrahydropyran-2-yl group, A lahydropyran-14-yl group or a tetrahydropyran-14-yl group, preferably having the formula
- tetrahydrofuranyl group is a monovalent group derived from tetrahydrofuranka by removing one arbitrary hydrogen atom, and specifically, for example, a tetrahydrofuran-2-yl group or a tetrahydrofuran-1-yl group.
- the (4-tetrahydrovinyl) methyl group means a methyl group substituted with the above-mentioned tetrahydropyran-4-yl group.
- the (2-tetrahydrofuryl) methyl group means a methyl group substituted with the above-mentioned tetrahydrofuran-12-yl group.
- the (3-tetrahydrofuryl) methyl group means a methyl group substituted with the aforementioned tetrahydrofuran-3-yl group.
- the "C alkyl group” is a straight-chain or branched alkyl having 1 to 6 carbons.
- the "C cycloalkyl group” is a monocyclic or bicyclic saturated oil having 3 to 10 carbon atoms.
- An aliphatic hydrocarbon group specifically, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclono group
- a cyclopropyl group a cyclobutyl group and a cyclopentyl group, and more preferably a cyclopropyl group.
- the "C alkoxy group” is a group in which an oxygen atom is bonded to the terminal of the above-defined "C alkyl group”.
- Group 2-methyl-2-propoxy group (t-butoxy group), 1-butoxy group (n-butoxy group), 2-butoxy group (sec-butoxy group), 1 pentyloxy group, 2 pentyloxy group, 3 pentyloxy group, 2 —Methyl-1-butoxy, 3-methyl-1-butoxy, 2-methyl-2-butoxy, 3-methyl-2-butoxy, 2,2-dimethyl-1-propoxy, 1-hexyloxy, 2-hexyloxy, 3 -Hexyloxy, 2-methyl-1 pentyloxy, 3-methyl-1 pentyloxy, 4-methyl-1 pentyloxy, 2-methyl-2 pentyloxy, 3 -Methyl-2 pentyloxy group, 4-methyl-2 pentyloxy group, 2-methyl-3 pentyloxy group, 3-methyl-3 penty
- the solvation in the compound ( ⁇ ) of the present invention or a salt thereof or a solvate thereof is not particularly limited as long as it forms a solvation with the compound ( ⁇ ) of the present invention or a salt thereof. Is a form in which the solvent forms a solvate at an appropriate ratio of 0.1 to 5 molecules to 1 molecule of the compound.
- Solvents for solvation include dimethyl carbonate, getyl carbonate, methyl acetate, ethyl acetate, isopropyl acetate, isopropanol, n-propanol, and ethanol.
- the salt of the compound ( ⁇ ) of the present invention is not particularly limited as long as it forms a salt with the compound ( ⁇ ) of the present invention, and examples thereof include a salt with an inorganic acid, a salt with an organic acid, and an acid. Examples thereof include salts with amino acids, and among them, pharmacologically acceptable salts are preferable.
- the acid forms a salt at an appropriate ratio of 0.1 to 5 molecules to 1 molecule of the compound.
- Preferred examples of the salt with an inorganic acid include, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Preferred examples of the salt with the organic acid include acetic acid, Examples include salts with succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, P-toluenesulfonic acid, and the like.
- salt with an acidic amino acid include, for example, salts with aspartic acid, glutamic acid and the like.
- Preferred examples of the salt of the compound (II) of the present invention include salts with hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, or hydrobromic acid. And salts with toluenesulfonic acid.
- Step 1A is a step of obtaining compound ( ⁇ ) by subjecting compound (I) to an aerondination using an organometallic reagent, followed by reaction with pentafluoroiodobenzene.
- the conditions of the reaction, treatment, purification, and the like in Step 1A will be described.
- the reaction can be performed with reference to Production Examples 6, 14, and 15 below.
- the compound (I) can be produced by the method described in the following Examples 3, 4, 5, WO02 / 088121, WO03 / 078435, WOO OZ59908, WOOOZ59907, and the like.
- the reaction between (I) and pentafluoroiodobenzene is carried out by the reaction of tetrahydrofuran, 1,2-dimethoxyethane, methinolate, butynoleate, cyclopentinolemethineoleate, diethyl ether, diisopropyl ether, diisopropyl ether.
- the reaction is performed in an organic solvent such as an ether solvent such as butyl ether and dicyclopentyl ether, a hydrocarbon-based aromatic ring solvent such as benzene and toluene, and a hydrocarbon-based solvent such as heptane and hexane.
- the organic solvent include ether solvents, and more preferable examples include tetrano and furan.
- the aonization reaction of compound (I) with the organometallic reagent, and the reaction of aroonized compound (I) with pentafluoroiodobenzene are carried out at 0 ° C. or lower (inner temperature in the reaction vessel).
- the reaction can be carried out preferably at a temperature of 30 ° C or less (inner temperature in the reaction vessel) using a dry ice ethanol bath or the like, and more preferably at a temperature of 130 to 175 ° C. More preferably, the reaction can be carried out at ⁇ 40 to ⁇ 75 ° C.
- the anionization reaction of compound (I) using an organometallic reagent can be carried out by dropping an organometallic reagent into a solution of the above-mentioned organic solvent of compound (I), or by adding a solution of the organometallic reagent to the above-mentioned organic solvent.
- the reaction can be carried out by dropping a solution in which the compound (I) is dissolved in the above organic solvent.
- the above-mentioned organometallic reagent means an organolithium compound (n-butyllithium, t-butyllithium, sec-butyllithium, phenyllithium, lithium diisopropylamide, etc.), an organoid, etc., an organic alkaline earth metal compound, etc.
- Preferred examples of the metal reagent include organolithium compounds, more preferred examples include n-butyllithium, t-butyllithium, and sec-butyllithium, and more preferred examples include n-butyllithium. Butyl lithium can be mentioned.
- the above-mentioned organometallic reagent can be used in an amount of 1.0 to 2.0 times the molar amount of compound (I), preferably in an amount of 1.4 to 1.6 times the molar amount. More preferably, it can be carried out using a 1.5-fold molar amount.
- reaction time of the anionization reaction of compound (I) with the above-mentioned organometallic reagent is not particularly limited, but it is preferable to perform stirring at the above-mentioned reaction temperature for 30 minutes to 2 hours after adding the reagent, and to stir for about 1 hour. Is more preferably performed.
- the reaction between the aforionized compound (I) and pentafluoroiodobenzene is carried out in a solution of the aforonated compound (I) in the above organic solvent.
- a solution of the solvent is added dropwise, or a solution of the above-mentioned organic solvent of the compound (I) is prepared by dropping a solution of pentafluoroiodobenzene in the above-mentioned organic solvent.
- the reaction is carried out by dropping a solution of pentafluoroiodobenzene in the above-mentioned organic solvent into a solution of the above-mentioned organic solvent in the above-mentioned organic solvent.
- Pentafluoroiodobenzene can be used in an amount of 1.0 to 2.0 times the molar amount of Compound (I), preferably in a 1.4 to 1.6 times molar amount. It can be carried out preferably using a 1.5-fold molar amount.
- the reaction time of the compound (I) with pentafluoroiodobenzene is not particularly limited, but it is preferable to stir at the above reaction temperature for 30 minutes to 2 hours after adding the reagent. Better More preferably, stirring is performed for about 1 hour.
- the reaction is carried out at the above reaction temperature or at a temperature between the reaction temperature and room temperature. Water, (2) water and tetrahide mouth furan, or (3) iodine, etc. in some cases.
- Iodine When adding iodine, then (2) water, furan at tetrahide, aqueous solution of sodium thiosulfate, etc. are added.
- Iodine can be used in an amount of 1.0 to 2.0 times the molar amount of pentafluoroiodobenzene, preferably in an amount of 1.4 to 1.6 times the molar amount. And preferably using a 1.5-fold molar amount.
- the extraction treatment can be performed after the aqueous layer is made acidic with an aqueous acid solution such as 5N hydrochloric acid, or can be performed after the aqueous layer is made alkaline with an aqueous alkaline solution such as a 5N aqueous sodium hydroxide solution. Extraction processing can be performed.
- Step 2A is a step of obtaining compound (lib) which is a hydrochloric acid form of compound ( ⁇ ) from compound ( ⁇ ) (salt Acidification).
- Step 2A The conditions of the reaction, treatment, purification and the like in Step 2A will be described. As a specific example, the reaction can be performed with reference to Production Example 7 below.
- the compound (II) can be produced by the method described in WO02 / 088121, WO03 / 078435, WOOO / 59908, WOOO Z59907 and the like.
- the compound ( ⁇ ) is dissolved in an organic solvent (preferably dimethyl carbonate, getyl carbonate and isopropanol, n-propanol, etc.), and then a solution of hydrogen chloride is added to the solution—10 to 90 ° C (preferably room temperature). For 1 to 24 hours (preferably 14 to 16 hours). The mixture is then brought to 20--10 ° C (preferably 5-10 ° C). At this time, the above-mentioned organic solvent may be appropriately added to the above-mentioned organic solvent to obtain the calories.
- an organic solvent preferably dimethyl carbonate, getyl carbonate and isopropanol, n-propanol, etc.
- the mixture is further stirred for 1 to 10 hours (preferably 1 to 3 hours), and a precipitate in the mixture is collected by filtration.
- the precipitate obtained by filtration is appropriately washed with dimethyl carbonate, getyl carbonate, heptane, hexane, water, or the like to obtain the desired compound (lib). Drying can be performed under conditions such as reduced pressure.
- the organic solvent used in the hydrochloride process may be a combination of dimethyl carbonate, ethyl carbonate, ethyl acetate, isopropanol, n-propanol, t-butyl methyl ether, heptane, hexane, and the like.
- Examples of the solution of hydrogen chloride include concentrated hydrochloric acid, diluted hydrochloric acid, ethyl acetate hydrochloride solution, methanol solution of hydrochloric acid, and the like.
- step 3A the compound ( ⁇ ) is reacted with the compound (IV) in the presence of a metal catalyst, a phosphate (or a carbonate can be used instead of the phosphate) and an amine compound.
- a metal catalyst e.g., a phosphate (or a carbonate can be used instead of the phosphate) and an amine compound.
- Compound (III) can be produced by the methods described in the following Examples, WO02 / 088121, WO03Z078435 and the like.
- Metal catalyst, phosphate, amine compound, compound (III) and compound (IV) are converted into an organic solvent (such as toluene, xylene, diglyme, dietoxetane, N, N-dimethylformamide, N-methylpyrrolidone). Dissolve and stir at 50-200 ° C (preferably 90-150 ° C, more preferably about 110 ° C) for 3-48 hours (preferably 14-16 hours).
- organic solvent such as toluene, xylene, diglyme, dietoxetane, N, N-dimethylformamide, N-methylpyrrolidone.
- the metal catalyst examples include a catalyst used in a coupling reaction such as a copper catalyst or a palladium catalyst, and the metal catalyst is preferably a copper catalyst.
- Examples of the copper catalyst include copper iodide (1), copper iodide (11), copper bromide (1), copper bromide (11), copper chloride (1), copper chloride (1), acetic acid and the like. It means copper (1), copper acetate (11), copper oxide, and the like. Preferred examples of the copper catalyst include copper iodide.
- Palladium catalysts include Pd (OAc) and Pd (dba) used in coupling reactions.
- the catalyst is not particularly limited as long as it is a catalyst.
- the phosphate include tripotassium phosphate, dipotassium hydrogen phosphate, trisodium phosphate, disodium hydrogen phosphate, trilithium phosphate, dilithium hydrogen phosphate or magnesium phosphate, or water thereof.
- Preferred examples of the force phosphate, which means a hydrate include tripotassium phosphate or a hydrate thereof, and a more preferred example is tripotassium phosphate hydrate.
- the carbonate include sodium carbonate, potassium carbonate, cesium carbonate, and hydrates thereof.
- the amine conjugate is not particularly limited as long as it is an amine compound which can be used as a ligand in a coupling reaction performed using a copper catalyst or a palladium catalyst.
- the compound (IV) can be used in an amount of 1.0 to 3.0 times the molar amount of the compound (III), preferably 1.0 to 1.5 times the molar amount of the compound (III). It can be carried out using an amount, more preferably using a 1.5-fold molar amount.
- the copper catalyst can be used in an amount of 0.001 to 1.0 times by mole, preferably 0.15 to 0.25 times by mole, based on the compound ( ⁇ ). More preferably, it can be carried out using a 0.2-fold molar amount.
- Phosphate can be carried out using a 1.0- to 5.0-fold molar amount to the compound ( ⁇ ), preferably using a 1.5- to 2.5-fold molar amount. More preferably, it can be carried out using a 2.0-fold molar amount.
- the amount of the carbonate used is the same as that of the phosphate.
- the amine compound can be used in an amount of 0.001-1.01 times the molar amount of the compound ( ⁇ ), preferably in an amount of 0.35-0.45 times the molar amount. It can be carried out using a 0.4-fold molar amount.
- organic solvent in the extraction treatment with the organic solvent Z water ethyl acetate, t-butyl methyl ether, toluene and the like can be used, and the extraction treatment can be performed one or more times.
- reaction treatment a method of adding water to the reaction mixture and then filtering is also available.
- the separated organic layer was washed twice with a 10% aqueous sodium thiosulfate solution, and then concentrated under reduced pressure. Hexane was added to the obtained residue, and after dissolution by heating, the hexane solution was filtered to remove insolubles. The hexane solution was washed with water and concentrated under reduced pressure. Next, the obtained residue was dissolved in ethyl acetate, and the solvent was distilled off under reduced pressure to obtain 663 g of the title compound (yield 98.9%).
- Be c gift 1m Be c ⁇ ) S08S ⁇ ⁇ ⁇ 09, ⁇ , tsu
- the precipitate was collected by filtration, washed with a mixed solution of t-butyl methyl ether and heptane (1: 3, 3.75 mL), and dried at 40 ° C for 24 hours to obtain 12.4 g of the title compound. Rate 71.8%).
- the organic layer was separated.
- the organic layer is further washed with water (10 mL), and then 5N hydrochloric acid (10 mL) is added, and the organic layer and the aqueous layer are sufficiently shaken. I'm sorry.
- the solvent was distilled off under reduced pressure to recover pentafluoroiodobenzene.
- the aqueous layer was cooled in an ice water bath, 5N aqueous sodium hydroxide solution (9 mL) was added, and then toluene (10 mL) was added. After thoroughly shaking the mixture of the organic layer and the aqueous layer, the organic layer was separated. I took it. The aqueous layer was re-extracted with toluene (10 mL) and extracted. The organic layers were combined and concentrated to give 632 mg of the title compound as a dark green oil (yield 90%).
- N cyclopropylmethyl-2ethyl-N (tetrahydro-2H-pyran-1-ylmethyl) pyrazo opening [1,5-a] pyridine-13amine (1.27 g, 4. O5mmo 1) was cooled in a dry ice Z ethanol bath.
- n-butyllithium 1.6 M hexane solution; 3.85 mL, 6.08 mmol
- N-cyclopropylmethyl-2-ethyl 7-horde N- (tetrahydrid-2H-pyran-14-ylmethyl) pyrazo-port [1,5-a] pyridine-13amine hydrochloride (16g) to saturated sodium bicarbonate ( (200 mL) was neutralized, and ethyl acetate (100 mL) was added, and the organic layer was separated. The solvent was distilled off from the organic layer under reduced pressure. Acetonitrile (30 mL) and water (120 mL) were added dropwise to the obtained residue, and after stirring overnight, the resulting precipitate was collected by filtration. The precipitate was dried under reduced pressure to obtain 13 g of the title compound as white crystals.
- toluene 2000 mL was added to the reaction mixture, and the separated aqueous layer was removed.
- This toluene layer was extracted twice with 5N hydrochloric acid (first time: 3000 mL, second time: 100 mL).
- Isopropyl acetate 2000 mL was added to the aqueous layer, and while cooling in an ice water bath, a 5N aqueous sodium hydroxide solution (4200 mL) was added to adjust the pH to 14, and the isopropyl acetate layer was separated.
- the isopropyl acetate layer was washed with a 10% aqueous solution of ethylenediamine (three times with 2000 mL) and water (twice with 2000 mL), concentrated, and azeotroped with ethanol (400 mL). The reaction mixture was concentrated. 207 g of a green solid was obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067021332A KR101117412B1 (ko) | 2004-04-12 | 2005-04-08 | 피라졸 축합환 유도체의 제조 방법 |
US11/578,134 US7858809B2 (en) | 2004-04-12 | 2005-04-08 | Process for production of pyrazole-fused ring derivatives |
CN2005800109060A CN1942468B (zh) | 2004-04-12 | 2005-04-08 | 吡唑缩合环衍生物的制造方法 |
CA2562578A CA2562578C (en) | 2004-04-12 | 2005-04-08 | Process for production of pyrazole-fused ring derivatives |
AU2005233430A AU2005233430B2 (en) | 2004-04-12 | 2005-04-08 | Process for production of pyrazole-fused ring derivatives |
JP2006512315A JP4927537B2 (ja) | 2004-04-12 | 2005-04-08 | ピラゾール縮合環誘導体の製造方法 |
IL178491A IL178491A (en) | 2004-04-12 | 2006-10-05 | DERIVATIVE OF PYRAZOLO [1,5-a]PYRIDINE-3-AMINE AND PROCESS FOR PREPARING SAME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004116611 | 2004-04-12 | ||
JP2004-116611 | 2004-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005100354A1 true WO2005100354A1 (ja) | 2005-10-27 |
Family
ID=35149935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006928 WO2005100354A1 (ja) | 2004-04-12 | 2005-04-08 | ピラゾール縮合環誘導体の製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7858809B2 (ja) |
JP (1) | JP4927537B2 (ja) |
KR (1) | KR101117412B1 (ja) |
CN (1) | CN1942468B (ja) |
AU (1) | AU2005233430B2 (ja) |
CA (1) | CA2562578C (ja) |
IL (1) | IL178491A (ja) |
WO (1) | WO2005100354A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009051210A1 (ja) | 2007-10-18 | 2009-04-23 | Eisai R & D Management Co., Ltd. | ピラゾール縮合環誘導体の製造方法 |
JP2012513962A (ja) * | 2008-12-24 | 2012-06-21 | シンジェンタ リミテッド | アリールアミドの製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085838A1 (en) * | 2001-04-24 | 2002-10-31 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
WO2002088121A1 (fr) * | 2001-04-27 | 2002-11-07 | Eisai Co., Ltd. | Pyrazolo[1,5-a] pyridines et medicaments les contenant |
WO2004037822A1 (ja) * | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 7−フェニルピラゾロピリジン化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3942357A1 (de) * | 1989-12-21 | 1991-06-27 | Boehringer Mannheim Gmbh | 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel |
WO2000059907A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolotriazines as crf antagonists |
WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
JP2005526090A (ja) * | 2002-03-13 | 2005-09-02 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 神経伝達物質調節因子としてのピラゾロ(1,5−a)ピリジン誘導体 |
US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
-
2005
- 2005-04-08 CN CN2005800109060A patent/CN1942468B/zh not_active Expired - Fee Related
- 2005-04-08 AU AU2005233430A patent/AU2005233430B2/en not_active Ceased
- 2005-04-08 JP JP2006512315A patent/JP4927537B2/ja not_active Expired - Fee Related
- 2005-04-08 US US11/578,134 patent/US7858809B2/en not_active Expired - Fee Related
- 2005-04-08 WO PCT/JP2005/006928 patent/WO2005100354A1/ja active Application Filing
- 2005-04-08 KR KR1020067021332A patent/KR101117412B1/ko not_active IP Right Cessation
- 2005-04-08 CA CA2562578A patent/CA2562578C/en not_active Expired - Fee Related
-
2006
- 2006-10-05 IL IL178491A patent/IL178491A/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085838A1 (en) * | 2001-04-24 | 2002-10-31 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
WO2002088121A1 (fr) * | 2001-04-27 | 2002-11-07 | Eisai Co., Ltd. | Pyrazolo[1,5-a] pyridines et medicaments les contenant |
WO2004037822A1 (ja) * | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 7−フェニルピラゾロピリジン化合物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009051210A1 (ja) | 2007-10-18 | 2009-04-23 | Eisai R & D Management Co., Ltd. | ピラゾール縮合環誘導体の製造方法 |
US20100217001A1 (en) * | 2007-10-18 | 2010-08-26 | Keizo Sato | Method for producing pyrazole fused ring derivative |
JP2012513962A (ja) * | 2008-12-24 | 2012-06-21 | シンジェンタ リミテッド | アリールアミドの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101117412B1 (ko) | 2012-02-29 |
IL178491A0 (en) | 2007-02-11 |
CA2562578A1 (en) | 2005-10-27 |
AU2005233430A1 (en) | 2005-10-27 |
AU2005233430B2 (en) | 2010-11-25 |
CA2562578C (en) | 2013-04-02 |
CN1942468B (zh) | 2011-06-22 |
IL178491A (en) | 2012-09-24 |
JP4927537B2 (ja) | 2012-05-09 |
CN1942468A (zh) | 2007-04-04 |
KR20070014149A (ko) | 2007-01-31 |
US20070191613A1 (en) | 2007-08-16 |
JPWO2005100354A1 (ja) | 2008-03-06 |
US7858809B2 (en) | 2010-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750167B2 (en) | Process for the preparation of asenapine and intermediate products used in said process | |
JP2021536471A (ja) | メチル6−(2,4−ジクロロフェニル)−5−[4−[(3s)−1−(3−フルオロプロピル)ピロリジン−3−イル]オキシフェニル]−8,9−ジヒドロ−7h−ベンゾ[7]アンヌレン−2−カルボキシレートの塩およびその製造方法 | |
JP2010503611A (ja) | アセナピンを調製するための方法、および前記方法で使用される中間生成物 | |
BG63691B1 (bg) | Циклоалканопиридини | |
WO2007058305A1 (ja) | シンナミド誘導体の製造方法 | |
WO2007102499A1 (ja) | 4-オキソキノリン化合物の製造方法 | |
JP2007505075A (ja) | キノリン化合物およびそれを含む医薬組成物 | |
NO301008B1 (no) | Metanoantracenforbindelser og farmasöytiske preparater inneholdende dem | |
WO2005100354A1 (ja) | ピラゾール縮合環誘導体の製造方法 | |
WO2010098332A1 (ja) | 多環式化合物の製造法およびその中間体 | |
JP5714744B2 (ja) | 置換イソキノリンを合成するための方法 | |
EP1999110B1 (en) | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | |
KR100430575B1 (ko) | 란소프라졸 및 그 중간체의 제조방법 | |
JP6321889B2 (ja) | イブチニブ中間体化合物、その製造方法及び用途 | |
WO2008032702A1 (fr) | Composé de fluorobore ayant un noyau aromatique ou sel de celui-ci, et procédé de fabrication du composé ayant un noyau aromatique fusionné à un éther cyclique à l'aide de celui-ci | |
JP7424115B2 (ja) | エステル化合物の製造方法 | |
JP7046868B2 (ja) | ジアリールメタン化合物の製造方法 | |
JP2002533334A (ja) | 抗ヒスタミン活性を有する三環式化合物を調製するためのプロセス | |
JP6570301B2 (ja) | 4−フルオロイサチン誘導体の製造方法 | |
WO2006068102A1 (ja) | 2-(ピラゾール-1-イル)ピリジン誘導体 | |
WO2019230864A1 (ja) | ジアリールメタン化合物の製造方法 | |
JP2002088061A (ja) | ベンゾキノン誘導体の新規製造方法 | |
JPH09301975A (ja) | ピロロキノリン誘導体 | |
JP2003221394A (ja) | キヌクリジン誘導体の製造方法 | |
JPWO2011030537A1 (ja) | 4−(5−メチルピリジン−2−イルアミノ)ピペリジン−1−カルボン酸誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512315 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005233430 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 178491 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11578134 Country of ref document: US Ref document number: 2007191613 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2562578 Country of ref document: CA Ref document number: 200580010906.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067021332 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005233430 Country of ref document: AU Date of ref document: 20050408 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005233430 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4147/CHENP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067021332 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 11578134 Country of ref document: US |